 Harpoon Therapeutics Inc NASDAQ: HARP presented a poster with interim data from the ongoing dose-escalation portion of the Phase 12 trial for HPN217 in patients with relapsedrefractory multiple myeloma. Data were presented at the American Society for Hematology ASH Annual Meeting and Exposition. 